Suter, Todd M.
Eli Lilly (United States)
2 papers on CoChatORCID 0009-0006-1242-9295
Most cited papers
- Verified
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight
Diabetes Treatment and ManagementReceptor Mechanisms and Signaling
Cited by 541
- Verified
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., et al. (2024) · Science Translational Medicine
Diabetes Treatment and ManagementReceptor Mechanisms and Signaling
Cited by 52
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free